Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIETAI-LACC phase II trial in locally advanced cervical cancer
ChiCTR2600134606Phase 2Recruiting
- Sponsor
- Chongqing Qianjiang Central Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in Cervical Cancer (CC), sponsored by Chongqing Qianjiang Central Hospital. Primary endpoints: Progression-free survival and Clinical complete response rate. Started Nov 2025; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600134606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134606.